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Abstract
Hypernatremia stimulates the secretion of oxytocin (OT), but the physiological role of OT remains unclear. The present study
sought to determine the involvement of OT and renal nerves in the renal responses to an intravenous infusion of hypertonic
saline. Male Wistar rats (280–350 g) were anesthetized with sodium thiopental (40 mg. kg21, i.v.). A bladder cannula was
implanted for collection of urine. Animals were also instrumented for measurement of mean arterial pressure (MAP) and
renal blood flow (RBF). Renal vascular conductance (RVC) was calculated as the ratio of RBF by MAP. In anesthetized rats
(n = 6), OT infusion (0.03 mg N kg21, i.v.) induced renal vasodilation. Consistent with this result, ex vivo experiments
demonstrated that OT caused renal artery relaxation. Blockade of OT receptors (OXTR) reduced these responses to OT,
indicating a direct effect of this peptide on OXTR on this artery. Hypertonic saline (3 M NaCl, 1.8 ml N kg21 b.wt., i.v.) was
infused over 60 s. In sham rats (n = 6), hypertonic saline induced renal vasodilation. The OXTR antagonist (AT; atosiban,
40 mg N kg21 N h21, i.v.; n = 7) and renal denervation (RX) reduced the renal vasodilation induced by hypernatremia. The
combination of atosiban and renal denervation (RX+AT; n = 7) completely abolished the renal vasodilation induced by
sodium overload. Intact rats excreted 51% of the injected sodium within 90 min. Natriuresis was slightly blunted by atosiban
and renal denervation (42% and 39% of load, respectively), whereas atosiban with renal denervation reduced sodium
excretion to 16% of the load. These results suggest that OT and renal nerves are involved in renal vasodilation and
natriuresis induced by acute plasma hypernatremia.
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Introduction
Hypernatremia constitute a challenge that threatens the survival
of the organism. Despite the wide variation in daily intakes and
losses of sodium, its concentration in the body fluids must be
maintained within narrow limits. Therefore, maintenance of the
plasma sodium concentration within a strict range is a central goal
of homeostatic mechanisms [1,2]. It is no surprise that multiple
mechanisms are involved in the regulation of sodium concentra-
tion. This wide variety of mechanism ranges from localized and
highly specific renal control of sodium loss to the complex
regulation of ingestive behaviors [3–5].
The central nervous system (CNS) detects variations in the
volume, tonicity, and composition of the extracellular compart-
ment through peripheral and central receptors. Once detected,
changes in plasma sodium concentration trigger centrally driven
behavioral and neurovegetative adjustments in order to correct
deviations [3,4]. Behavioral responses consist of thirst and sodium
appetite. The neurovegetative adjustments include changes in
renal excretion of water and sodium. Indeed, hypertonicity
reduces sympathetic renal nerve activity [5–8], induces renal
vasodilatation [9–12], and increases release of vasopressin (VP),
atrial natriuretic peptide (ANP) [13,14] and oxytocin (OT) [15–
18]. Together, these adjustments lead to natriuresis [19–22].
Renal vascular tone is a significant factor in the regulation of
water and sodium excretion, and it is one of the variables adjusted
in response to acute variations in the osmolality of the extracellular
fluid [10,11,23]. The mechanisms involved in the genesis and
maintenance of the renal vasodilation induced by increases in the
plasma sodium concentration are complex and appear to involve
neural and humoral mechanisms.
Oxytocin is well known for its role in uterine contraction [24]
and milk ejection [25], but has several additional functions, many
related with social behavior, maternal care, sexual behavior,
learning and memory (for review see [26,27]). In addition, OT
seems to be involved in the responses to changes in body fluid
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osmolality. OT secretion is increased in response to alterations in
the plasma sodium concentration [17,28], and its infusion
increases urinary volume [29,30], glomerular filtration [29,31],
and urinary excretion of sodium in rats [30,32–35]. These effects
are mediated by the interaction of OT with the OXTR receptor, a
G protein-coupled receptor that is coupled to phospholipase C
through Gaq11 [26,36].
Stimulation of the renal nerve reduces sodium excretion
through secretion of renin, renal vasoconstriction, and increased
tubular reabsorption of sodium [37]. Renal sympathetic activity is
reduced by plasma hypertonicity, leading to renal vasodilation and
natriuresis [5–8,23]. However, to the best of our knowledge, there
are no evidences that have evaluated if the secretion of OT is
related with renal vasodilation and natriuresis induced by
hypernatremia. Moreover, no other study sought to evaluate the
interaction between renal sympathetic activity and secretion of
OT on renal and cardiovascular responses induced by sodium
overload.
Therefore, in the present study, we tested the hypothesis that
OT and renal nerves may be involved in the cardiovascular and
renal responses induced by acute hypernatremia. For this purpose,
we assessed the effects of OXTR receptor blockade and renal
denervation on renal vasodilatation and natriuresis induced by
intravenous infusion of hypertonic saline. We also assessed the
effects of OT on renal vascular tone and resistance.
Results
OXTR gene expression in the renal artery
The qRT-PCR analysis indicated that t OXTR was expressed
in the renal artery (n = 10 arteries taken from 5 rats; Figure 1).
These findings demonstrated that OXTR gene was expressed as
b-actin, a constitutive gene. The Ct value was 32.0162.1 for
OXTR and 22.0861.3 for b-actin. The Melting curve confirms
the specific expression of OXTR gene in renal arteries
(Figure 1A). As control, the expression of b-actin gene was used
(Figure 1B).
Effect of OT on renal vascular resistance and on renal
artery rings
In vivo experiments demonstrated that the intravenous infusion
of OT (8, 16, or 30 ng N kg21, i.v.) in anesthetized rats (n = 6) did
not change mean arterial pressure (MAP; Figure 2A). All three
doses of OT increased renal blood flow (RBF; Figure 2A) and
renal vascular conductance (RVC; Figure 2A and B). Renal
vasodilation started immediately after infusion and lasted no
longer than 30 s. Ex vivo experiments showed that OT produced
a concentration-dependent relaxation in renal artery rings
(EC50= 0.9160.07 mmol N l21. Figure 2C; n= 6 rings taken from
5 rats) precontracted with 1 mmol N l21 phenylephrine, suggesting
a direct effect of OT on the renal artery.
Effect of blockade of OXTR and VP-receptors on renal
vasodilatation and vasorelaxation induced by OT
In vivo experiments demonstrate that the OXTR-antagonist,
Atosiban, reduced OT-induced renal vasodilatation (Figure 3A
and B, n = 6), whereas the V1 antagonist, Manning compound,
did not affect renal vasodilatation induced by OT (Figure 3C and
D, n= 6). Ex vivo experiments showed that the vasorelaxation
induced by 1 mM OT was significantly reduced in the presence of
the OXTR antagonist, Atosiban (1 mM, Figure 4A and C). The
vasopressin V1 antagonist, Manning Compound (0.1 mM) did not
reduce OT-induced vasorelaxation (Figure 4B and D), suggesting
a direct effect of OT on OXTRs in the renal artery.
Effects of hypertonic saline infusion on plasma sodium
and blood hemoglobin concentrations
The body weight and cardiovascular baseline values are shown
in Table 1. These variables were similar in sham and rats
subjected to OXTR-antagonist pretreatment (Atosiban; AT), renal
denervation (RX) and renal denervation and atosiban pretreat-
ment (RX+AT). In sham rats, intravenous infusion of hypertonic
saline (HS) caused a sustained (.60 min) increase of plasma Na+
concentration (Figure 5A). In AT and RX+AT, plasma Na+
concentration remained significant higher than in sham rats
(Figure 5A).
In sham rats, HS infusion did not change blood hemoglobin
concentration (Figure 5B). Combining HS with AT, RX, or both
did not alter changes in blood hemoglobin (Figure 5B).
Effects of OXTR blockade and renal denervation on
cardiovascular responses induced by HS infusion
In sham rats (n = 6), HS infusion caused a mild increase in MAP
(Figure 6A), without changing heart rate (HR; Figure 6B). Ten
minutes after the HS infusion, RBF and RVC were increased, and
they remained high after 60 min (Figure 6C–D). In AT rats
(n = 7), changes in MAP and HR were similar to those observed in
sham rats (Figures 6A–B), but the increases in RBF and RVC
were much reduced (Figures 6C–D). In RX rats (n = 6), HS
infusion did not change HR, but the pressor response (10 min
after HS) was increased, and renal vasodilation was blunted
(Figure 6). The combination of atosiban and renal denervation
(RX+AT rats, n = 7) potentiated the hypertensive response
(Figure 6A) and abolished the renal vasodilation induced by HS
infusion (Figure 6C–D).
Effects of blockade of OXTR and renal denervation on
urinary excretion induced by HS infusion
HS infusion increased urinary flow in sham rats (n = 6) at
10 min (Figure 7A). The diuresis caused by HS was reduced by
Atosiban (n= 7) and by renal denervation (n= 6), and was reduced
further by the combination of Atosiban and renal denervation
(n= 7; Figure 7A). Urinary sodium concentration increased after
infusion of HS. The increase of urinary sodium concentration after
sodium overload was higher in AT and RX (Figure 7B), but it was
reduced by the combination of RX+AT (Figure 7B). AT and RX
slightly reduced the amount of sodium, and RX+AT reduced it
further (Figure 7C). As a consequence, sham rats excreted 51% of
the injected sodium within 90 min, AT rats excreted 42%, RX
rats excreted 42%, and At+RX rats excreted only 16% of the load
(Figure 7D).
Effect of OXTR antagonist on cardiac mRNA for ANP
The effect of the OXTR antagonist, Atosiban, on cardiac
expression of the ANP gene was measured by qRT-PCR. Figure 8
demonstrated that pre-treatment with OXTR antagonist reduced
cardiac ANP gene expression in rats subjected to HS infusion.
Discussion
Previous studies indicate that intravenous administration of OT
increases urinary volume [29,30], glomerular filtration [29,31],
and urinary excretion of sodium [17,32,34,35]. However, the
participation of this hormone in the regulatory mechanisms
activated by an increase of plasma sodium concentration is yet to
be fully clarified. The present study provides the following
findings: i) the OXTR gene was expressed by the renal arteries;
ii) administration of OT promoted renal artery relaxation in vivo
Neuroendocrine Responses to Hypernatremia
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and ex vivo; iii) blockade of OXTR, but not VP-receptors,
reduced renal artery relaxation in vivo and ex vivo induced by
OT; iv) blockade of OXTR and renal denervation reduced renal
vasodilation and natriuresis induced by acute hypernatremia; v)
the combination of OXTR antagonist and renal denervation
completely abolished the renal vasodilation and further reduced
natriuresis induced by sodium load; and vi) cardiac ANP gene
expression induced by HS infusion was decreased in the presence
of OT receptors antagonist. Collectively, these results suggest that
the renal vasodilation and natriuresis induced by sodium overload
is mediated by the combined action of OT and renal nerves.
Changes in the osmolarity of the extracellular compartment
affect all tissues and may alter cell volume, metabolism, and
function [1]. Acute alterations in osmolarity may induce convul-
sions, paralysis, coma, and in extreme conditions, death [2,4].
Thus, the precise regulation of the osmolality and therefore
intracellular volume is critical for survival. Disturbances in these
regulatory mechanisms have been associated with the pathophys-
iology of cardiovascular diseases, particularly hypertension [38–
40], and with diseases related to renal sodium retention, such as
cirrhosis and heart failure.
The present study demonstrated that OT induced a concen-
tration-dependent relaxation in renal arteries both in vivo and
in vitro. The complex mechanisms involved in the genesis and
maintenance of the renal vasodilation induced by increases plasma
sodium concentration are poorly understood and seem to involve
hormonal and autonomic mechanisms [8,10,14,41,42]. Our
in vitro results show that OT can act on oxytocin receptors in
the renal vasculature to promote vasodilatation. Experimental
evidence has demonstrated that hypernatremia induces OT
secretion [15,17,28]. Huang et al. (1995) [17] showed that infusion
of hypertonic saline stimulates OT secretion and natriuresis. Our
data showed that the blockade of OXTR abolished the
vasodilation and reduced the natriuresis induced by a sodium
overload. Together, these results indicate that OT is involved in
the cardiovascular and renal responses to an increase in plasma
sodium concentration. To the best of our knowledge, there is no
other evidence that OT mediates renal vasodilation induced by
hypernatremia. Although HS increased plasma sodium concen-
tration, it did not significantly reduce blood hemoglobin,
suggesting blood volume did not change. This is consistent with
previous studies using the same protocol [10,11,13,14,23].
Therefore, it is likely that the cardiovascular and renal adjustments
induced by HS infusion were due to increased sodium concentra-
tion rather than to volume expansion.
It has been proposed that the natriuresis and renal vasodilata-
tion induced by OT are due to cardiac OXTR receptors that
stimulate ANP release [30,35,43,44]. In the present study we
demonstrated that an OXTR antagonist reduced cardiac ANP
gene expression induced by HS infusion. Our result is consistent
with studies conducted by Haanwinckel et al. [30], who
demonstrated that the intraperitoneal or intravenous administra-
tion of OT causes an increase in the plasma concentration of ANP.
Moreover, Gutkowska and coworkers [44] demonstrated that
OXTR were functional and important for the secretion of ANP, as
OXTR blockade reduces the release of ANP induced by OT
administration. Once in the circulation, ANP stimulates renal
vasodilation and natriuresis [47]. We also demonstrated that OT
can act directly on the renal arteries to cause renal relaxation.
Overall, these findings suggest that OT can act both directly and
indirectly (via ANP) to promote renal vasodilatation.
Neural mechanisms also regulate sodium excretion. Renal nerve
stimulation promotes renin secretion, renal vasoconstriction, and
tubular sodium reabsorption [37], reducing renal sodium losses.
Figure 1. Melting curve showing the specific expression of the OXTR gene in renal arteries of rats after qRT-PCR analyses (A).
Expression of the control gene B-actin was used (B).
doi:10.1371/journal.pone.0109620.g001
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Plasma hypernatremia inhibits renal sympathetic activity, stimu-
lating sodium excretion [5–7]. A previous study from our
laboratory [8] has shown that renal denervation slightly reduces
the renal vasodilation induced by sodium overload, suggesting this
vasodilation is partly a consequence of renal sympathoinhibition.
Furthermore, in the present study we demonstrated that a
combination of renal denervation and OXTR blockade abolished
renal vasodilation and sharply reduced the natriuresis. Taken
together, these results suggest an additive effect of OT secretion
and renal nerves on natriuresis and renal vasodilatation induced
by a sodium overload. In the present study we also observed that
pressor responses to a sodium overload are greater in rats
subjected to renal denervation and blockade of OXTR. Several
other studies that blocked hypernatremia-induced renal vasodila-
tion similarly reported an increase in the magnitude and duration
of the hypertensive response [7,10–12]. A decade ago, it was
proposed that hypernatremia initially stimulates secretion of
vasoactive peptides (ANP and OT) and reduces renal sympathetic
activity. This mechanism leads to reduction in renal vascular
resistance and sodium reabsorption, which culminates in sodium
excretion. If this initial mechanism fails to correct hypernatremia,
a generalized increase in sympathetic activity increases blood
pressure, leading to increases in renal perfusion pressure,
glomerular filtration rate and consequently natriuresis [3]. In the
light of these evidences, the increased pressor response to
hypernatremia observed in animals subjected to renal denervation
and blockade of OXTR could be due to the ineffectiveness of the
initial mechanism, resulting in a generalized increase in sympa-
thetic activity and consequent hypertension. It is noteworthy,
however, that the results obtained in the present study also
indicate that this pressure mechanism failed to stimulate sodium
excretion, since only 16% of of sodium load was excreted during
Figure 2. Typical tracing of changes in cardiovascular parameters induced by intravenous injection of vehicle (0.1 ml NaCl
150 mmol N l21) and oxytocin (0.008, 0.016 e 0.03 mg N kg21 b.wt., i.v.) in anesthetized rats (A). Effects of oxytocin or vehicle infusion on
renal vascular conductance (RVC) in anesthetized rats (B; n = 6). Concentration–response curve for relaxation of the isolated renal artery by oxytocin
(0.361026 to 361026 M; C - n = 6 rings taken from 5 rats). Error bars indicate S.E.M. Dashed line indicates oxytocin injection. AP = arterial pressure,
MAP = mean arterial pressure, RBF = renal blood flow, RVC = renal vascular conductance. *p,0.05 compared to vehicle.
doi:10.1371/journal.pone.0109620.g002
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the next 90 min in rats subjected both renal denervation and
blockade of OXTR.
Our results are compatible with the hypothesis that OT
secretion and renal nerves play an important role in renal
vasodilatation induced by hyperosmolarity. This strongly suggests
that both humoral (oxytocinergic) and autonomic (sympathoinhi-
bitory) mechanisms are important. The unbalance in one or both
these mechanisms may contribute to several pathological condi-
tions, including some models of experimental hypertension in
rodents.
Methods
Animals and ethics statement
All experiments were conducted on adult male Wistar rats (280–
350 g). Rats were obtained from the central animal house of the
Federal University of Goia´s. Experimental procedures were
designed in strict adherence to the National Health Institute
Guidelines for Care and Use of Laboratory Animals, and
approved by the Research Ethics Committee of the Federal
University of Goia´s (protocol number 034/12).
Molecular analysis of OXTR gene expression in the renal
artery
Total RNA was extracted from ten renal artery using Trizol
(Invitrogen Corporation, Carlsbad, CA, USA), chloroform was
added (1:5, v/v), and the aqueous phase was obtained after
centrifugation (12,0006g, 15 min). RNA was precipitated with
isopropanol for 15 min at room temperature, followed by
centrifugation at 12,0006g for 10 min. The pellets were
resuspended in water treated with 0.1% DEPC, and the RNA
content was quantified by spectrophotometry.
For reverse transcription, 2 mg of total RNA was used as a
template to synthesize cDNA. RNA was incubated with 1 ml
oligo(dt) 15–20 (0.5 pmol, Fermentas - Thermo Scientific, Vilnius,
Lithuania), and DEPC-water to a final volume of 12 ml, for 5 min
at 65uC. The following reagents were then added to reach a final
Figure 3. Typical tracing showing changes in cardiovascular parameters induced by intravenous infusion oxytocin (OT - 0.03 mg ?
kg21; b.wt., i.v.; in 0.1 ml) before and after administration of OT-antagonist (Atosiban; 40 mg ? kg21 b.wt., i.v.; A) or VP-antagonist
(Manning compound; 10 mg ? kg21 b.wt., i.v.; C). Effects of vehicle and OT infusion (0.008, 0.016 and 0.03 mg ? kg21 b.wt., i.v.) before and after
administration of OT-antagonist (B) and VP-antagonist (D) on renal vascular conductance (RVC; n = 6). The results are expressed as the mean 6 SEM.
The dashed line indicates the OT infusion. AP = arterial pressure, MAP = mean arterial pressure, RBF = renal blood flow and RVC = renal vascular
conductance. *different from vehicle (NaCl 0.15 M); {different from OT, both p,0.05.
doi:10.1371/journal.pone.0109620.g003
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Figure 4. Typical tracing showing the effect of OXTR antagonist (A) and VP receptor antagonist (B) on vasorelaxation induced by
OT (1 mM) in renal artery rings. Effects of pre-treatment with OT-Antagonist (C) and VP-antagonist on renal vasorelaxation induced by OT.
{different from OT, p,0.05.
doi:10.1371/journal.pone.0109620.g004
Table 1. Body weight and basal level of cardiovascular and renal variables in sham, rats pretreated with the oxytocin antagonist
atosiban (AT), renal denervated rats (RX) and rats pretreated with atosiban and renal denervation (RX+AT).
Group n b.wt. MAP HR RBF RVC
g mm Hg bpm ml N min21 mm Hg N (ml N min)21
Sham 6 30669 11562 340615 3.660.8 0.02960.004
AT 7 30766 11365 367612 4.560.7 0.03860.006
RX 6 30066 11563 359610 3.560.7 0.03160.007
RX-AT 7 30567 11067 354610 3.060.9 0.02160.003
Values are means 6 S.E.M. b.wt. = body weight, MAP = mean arterial pressure, HR = heart rate, RBF = renal blood flow, RVC = renal vascular conductance.
doi:10.1371/journal.pone.0109620.t001
Neuroendocrine Responses to Hypernatremia
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volume of 20 ml: 4 ml RT buffer (50 mM Tris–HCl, pH 8.3,
75 mM KCl, 3 mM MgCl2), 2 ml 10 mM dNTPs mix, 1 ml
RiboLock RNase inhibitor (20 U/ml) and 1 ml RevertAid H Minus
M-MuLV reverse Transcripase (200 ml/ml, Fermentas - Thermo
Scientific, Vilnius, Lithuania). The mixture was incubated for
5 min at 25uC followed by 60-min at 45uC and cDNA synthesis
was performeded at 70uC for 5 min.
qRT-PCR widely used for analysis of gene expression in tissue
(Applied Biosystems Step One Plus PCR System, Foster City, CA,
USA). We standardized a qRT-PCR method to analyze the
expression of the OXTR, using b-actin as a constitutive gene. For
OXTR we used as a forward primer: 5-CGA TTG CTG GGC
GGT CTT CA-3 and as a reverse primer 5-CCG CCG CTG
CCG TCT TGA G-3, resulting in a PCR product of 161 bp. For
b -actin, we used as a forward primer 5-AGA GGG AAA TCG
TGC GTG AC-3 and as a reverse primer 5-CAA TAG TGA
TGA CCT GGC CGT-3, resulting in PCR product of 138 bp.
For qRT-PCR amplification, 2 ml of the cDNA pool resulting
from the above reaction was used in a reaction containing PCR
buffer Maxima SYBR Green/ROX qRT-PCR Master Mix (2X)
(Fermentas – Thermo Scientific, Vilnius, Lithuania), 0.15 mM of
each primer and water to produce a final volume of 25 ml. General
qRT-PCR conditions were initial denaturation at 95uC for
10 minutes, followed by 40 cycles of 95uC for 15 s, annealing at
60uC for 1 min and extension at 72uC for 20 s. Amplification was
completed with an additional step at 72uC for 5 min. A melting
curve analysis was performed subsequent to amplification of the
target sequence. The program for melting curve analysis was 95uC
for 5 s, 65uC for 20 s, with 20uC/s transition rate and then
ramping to 98uC at 0.2uC/s.
Effect of OT on renal vascular resistance
Rats were anesthetized with 2–3% halothane in 100% O2 and
catheters were inserted into the right femoral vein and artery. A
catheter was inserted in the right jugular vein and advanced to
bring the tip close to the right atrium. Halothane was replaced by
sodium thiopental (40 mg N kg21, i.v.; Crista´lia Ltda, Itapira, SP,
Brazil). The trachea was cannulated to reduce airway resistance.
Miniature ultrasonic transit-time flow probes (Transonic Systems
Inc., Ithaca, NY, USA) were placed around the left renal artery.
The body temperature was kept at 3760.5uC with a thermostat-
ically controlled heated table.
Arterial pressure was measured from the arterial cannula with a
disposable pressure transducer. RBF was measured with an
ultrasonic transit-time flowmeter (Transonic Systems, Inc., Ithaca,
NY, USA). Data were recorded continuously with an MP150
analog-to-digital converter (Biopac Systems, Inc., Goleta, CA,
USA). MAP and HR were determined from the pulsatile signal
with AcqKnowledge software (version 3.7.1.; Biopac Systems, Inc.,
Goleta, CA, USA). The change of RVC was calculated as the ratio
of RBF by MAP, and expressed as a percentage of baseline values.
Increasing doses of OT (0.008, 0.016 and 0.03 mg N kg21, i.v.)
were infused. In additional rats, the vasopressin V1 antagonist,
Manning compound (10 mg N kg21 b.wt.; in 0.1 mL) was injected
i.v., followed by increasing doses of OT (0.008, 0.016 and
0.030 mg N kg21, i.v.). In additional rats, the OXTR antagonist,
Atosiban, was infused for 1 h, starting 30 min before increasing
doses of OT infusion. The total amount of Atosiban infused was
40 mg N kg21 in a volume of 3 ml N kg21.
Effect of OT on renal artery rings
Rats were anesthetized with halotane (2% in O2 100%)
(Crista´lia Ltda, Itapira, SP, Brazil) and decapitated. The renal
artery was cleaned of adhering fat and connective tissue, removed,
and cut in 2 mm long rings. Rings were placed in a warmed (37uC)
organ bath containing 10 ml of modified Krebs-Henseleit solution
(in mmol N l21: NaCl = 130, NaHCO3= 14.9, KCl = 4.7,
KH2PO4= 1.18, MgSO4= 1.17, CaCl2 = 1.6, glucose = 5.5;
pH=7.4, bubbled with 95% O2 and 5% CO2). Rings were
mounted on stainless steel hooks connected to isometric transduc-
ers. Tension was recorded with a data acquisition system (AVS
Projetos, Sa˜o Carlos, SP, Brazil). Rings were kept for 60 min with
a tension of 1.5 g. During this period, the Krebs-Henseleit solution
was changed every 15 min. Phenylephrine (1 mmol N l21) was
added to contract the rings. After tension stabilized (usually within
15 min), increasing concentrations (0.3 to 3 mmol N l21) of OT
were added. In additional experiments, the vasorelaxation induced
by 1 mM OT was measured in the absence or presence of the
OXTR antagonist, Atosiban (1 mM), or the V1 antagonist,
Manning compound (0.1 mM). At the end of the experiment, the
Figure 5. Effects of OXTR antagonist treatment (atosiban; AT),
renal denervation (RX) and the combination of AT and RX
(RX+AT) on changes in plasma sodium (A) and blood hemo-
globin concentration (B) induced by HS infusion (3 M NaCl,
1.8 ml N kg21 b.wt., i.v). Black bars indicate the moment of HS
infusion. *different from baseline, {different from sham, both p,0.05.
doi:10.1371/journal.pone.0109620.g005
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effectiveness of the endothelium was evaluated by observing the
response to 10 mmol N l21 acetylcholine.
Effect of OXTR antagonist and renal denervation on
cardiovascular and renal responses induced by
hypertonic saline
Additional rats were anesthetized and fitted with cannulas in the
femoral vein and artery and a flow probe around the renal artery,
as described above. The bladder was catheterized through a
suprapubic incision for collection of urine. About 60 min later,
hypertonic saline (3 M NaCl, 1.8 ml N kg21 b.wt., i.v.) was infused
over 60 s. In some rats, the selective OXTR antagonist, [Mpa1,
D-Try(Et)2, Thr4, Orn8]-OT (atosiban, Ferring, Sweden), was
infused for 1 h, starting 30 min before the infusion of hypertonic
NaCl. The total amount infused was 40 mg N kg21 in a volume of
3 ml N kg21. This dose has been shown previously to block the
natriuretic effects of OT but not to interfere with VP-receptors
[33,43].
In another group of rats (RX), the left and right kidney
innervation was removed surgically as previously described [8,45–
50]. Briefly, the renal arteries were dissected under a surgical
microscope, and the renal nerves running along them were
carefully removed. The connective tissue of the renal artery and
vein were stripped and the renal artery was coated with a solution
of 10% phenol in absolute alcohol.
In another group of rats, the innervation of the left and right
kidney was removed and the animals were submitted to atosiban
infusion 60 minutes after the renal denervation (RX+AT). In sham
rats, the renal artery was dissected and renal nerves bundles were
visualized and kept intact. These rats received the same volume
(3 ml N kg21) of saline (NaCl 150 mmols N l21).
Blood samples (0.20 ml each) were withdrawn from the arterial
cannula 10 min before and 10, 30, 60 and 90 min after i.v.
infusion of hypertonic saline. The sample was replaced by an equal
volume of sterile 150 mM NaCl. Blood hemoglobin concentration
was measured immediately with a kit from Sigma (Drabkin’s
reagent, kit 525). The rest of the sample was centrifuged for 5 min
at 6000 g. The plasma was removed and stored at 220uC.
Sodium concentrations in urine and plasma were measured with a
flame photometer (model DM6, Digimed, Sa˜o Paulo, Brazil).
The amount of sodium in the urine was determined by the
product of urine volume and sodium concentration. Sodium
balance was calculated as the difference between the amount
infused and the amount excreted.
Molecular analysis for ANP in heart
Rats were euthanized, the cardiac muscle was cut in small
pieces and frozen in liquid nitrogen. The tissues were disrupted by
vigorous mixing with glass beads as described before. qRT-PCR
analysis was performed in triplicate from a cDNA pool of each
treatment. For natriuretic peptide precursor A (ANP), we used as a
Figure 6. Effects of OXTR antagonist treatment (atosiban; AT), renal denervation (RX) and the combination of AT and RX (RX+AT)
on cardiovascular changes induced by intravenous HS infusion (3 M NaCl, 1.8 ml N kg21 b.wt., i.v). A) Mean arterial pressure (MAP). B)
Heart rate (HR). C) Renal blood flow (RBF). D) Renal vascular conductance (RVC). Black bars indicate the moment of HS infusion. Red bars indicate the
period of OXTR-antagonist infusion or saline (150 mmol ? l21 NaCl; Sham and RX groups). *different from baseline, {different from sham, $different
from atosiban, #different from RX, both at p,0.05.
doi:10.1371/journal.pone.0109620.g006
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forward primer 5-GGA TTT CAA GAA CCT GCT AGA-3, and
as a reverse primer 5-GCT TCA TCG GTC TGC TCG C-3,
resulting in a PCR product of 96 bp. For GAPDH, we used as a
forward primer 5-GTC GGT GTG AAC GGA TTT G-3, and as
a reverse primer 5-CCG CCG CTG CCG TCT TGA G-3, with a
PCR product of 150 bp. All primers were specific for Rattus
norvegicus. The data were normalized using the constitutive gene
GAPDH as the endogenous control, amplified in each set of qRT-
PCR experiments. Data were expressed as mean 6 standard
deviation of the triplicates of independent experiments. Standard
curves were generated by diluting the cDNA solution 1:5. Relative
expression levels of genes of interest were calculated using the
standard curve method for relative quantification [51].
Data analysis
Results are presented as means 6 S.E.M. Cardiovascular
baseline values and the effects of OT infusion and OXTR and VP-
antagonist were analyzed by one-way ANOVA. When groups
differed significantly, the Bonferroni post hoc test was used. The
effects of HS infusion on renal and cardiovascular parameters
were analyzed by two-way ANOVA. When groups differed
significantly, the LSD-Fisher post hoc test was used. Effects of
OT infusion and OXTR and VP-antagonist were analyzed by
one-way ANOVA. When groups differed significantly, the
Bonferroni post hoc test was used. The EC50 for the effect of
OT on vascular relaxation was obtained by linear regression of
vascular relaxation and the log of the OT concentration using
GraphPad Prism statistical software version 6.03 for Windows
(GraphPad Software, Inc., San Diego, CA, USA). Molecular data
were compared by the T test. A value of P,0.05 was considered to
denote a significant difference.
Figure 7. Effects of OXTR antagonist treatment (atosiban; AT), renal denervation (RX) and the combination of AT and RX (RX+AT)
on urinary changes induced by intravenous HS infusion (3 M NaCl, 1.8 ml N kg21 b.wt., i.v.). A) Urine flow. B) Urinary sodium
concentration. C) Cumulative urinary sodium. D) Sodium balance. Black bars indicate the moment of HS infusion. Red bars indicate the period of
OXTR-antagonist infusion or saline (150 mmol ? l21 NaCl; Sham and RX groups). *different from baseline, {different from sham, $ different from
atosiban, #different from RX, both at p,0.05.
doi:10.1371/journal.pone.0109620.g007
Figure 8. Effect of blockade of OXTR (Atosiban) on atrial
natriuretic peptide (ANP) mRNA in the heart of rats submitted
to HS infusion 3 M NaCl, 1.8 ml N kg21 b.wt., i.v. ANP mRNA levels
were assessed by the real-time quantitative reverse transcription
polymerase chain reaction. The results are presented as mean 6
standard deviation of the triplicates of independent experiments.
{different from Sham, at p,0.05.
doi:10.1371/journal.pone.0109620.g008
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